(Q50723376)

18 March 2018

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma (English)

1 reference

18 March 2018

0 references

1 reference

1 reference

10

1 reference

18 March 2018

Elliot S. Barnathan

9

object named as

Elliot S Barnathan

1 reference

18 March 2018

Trevor T. Hansel

12

object named as

Trevor T Hansel

1 reference

18 March 2018

Peter J. Barnes

11

object named as

Peter J Barnes

1 reference

18 March 2018

author name string

Edward M Erin

1

1 reference

18 March 2018

Brian R Leaker

2

1 reference

18 March 2018

Grant C Nicholson

3

1 reference

18 March 2018

Andrew J Tan

4

1 reference

18 March 2018

Linda M Green

5

1 reference

18 March 2018

Helen Neighbour

6

1 reference

18 March 2018

Angela S Zacharasiewicz

7

1 reference

18 March 2018

Jackie Turner

8

1 reference

18 March 2018

language of work or name

English

0 references

publication date

13 July 2006

1 reference

18 March 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

18 March 2018

volume

174

1 reference

18 March 2018

issue

7

1 reference

18 March 2018

page(s)

753-762

1 reference

18 March 2018

Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities

cites work

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Severe asthma: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Drug development for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

7. Control of allergic airway inflammation through immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

3. Cytokines and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Cytokine-directed therapies for the treatment of chronic airway diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

TNF alpha is important in human lung allergic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Historical review: Cytokines as therapeutics and targets of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Infliximab treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

First study of infliximab treatment in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Role of tumor necrosis factor alpha in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Evidence of a role of tumor necrosis factor alpha in refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Asthma refractory to glucocorticoids: the role of newer immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164/RCCM.200601-072OC

Trial of cyclosporin in corticosteroid-dependent chronic severe asthma

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Differentiating the efficacy of the tumor necrosis factor inhibitors

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Etanercept as monotherapy in patients with psoriasis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Making sense of asthma genes

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Managing severe asthma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Community-acquired pneumonia guidelines: much guidance, but not much evidence

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Update on glucocorticoid action and resistance

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Inhibition of tumor necrosis factor alpha for refractory asthma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide in Adults and Children—1999

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1164/RCCM.200601-072OC

Identifiers

DOI

10.1164/RCCM.200601-072OC

1 reference

18 March 2018

release_yqguxcmuwbb43nh5ci7l5g2ocu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yqguxcmuwbb43nh5ci7l5g2ocu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

18 March 2018